Biobot Surgical Pte Ltd

What Biobot Surgical Pte Ltd does

Biobot Surgical Pte Ltd is a Singapore-headquartered medical robotics company that developed and commercializes the iSR'obot Mona Lisa, a robotic platform for transperineal (percutaneous) prostate procedures. The platform combines Elastic MRI-Ultrasound Fusion imaging with robotic-assisted needle positioning to deliver sub-millimeter (within 1.0mm) accuracy for targeted prostate biopsies and, in its second generation, positioning for soft tissue ablation treatment. Biobot holds five key regulatory clearances across FDA, CE, NMPA, TGA, and HSA jurisdictions through two product generations — Mona Lisa [Dx] (launched 2017) for diagnostic biopsies and Mona Lisa 2.0 [Tx] (launched 2024) for ablation treatment positioning — with a pipeline product (ACCuESS) targeting expanded sites of care and indications.

The company monetizes through direct enterprise sales of the robotic system hardware to hospitals and urology centers, supplemented by consumables and procedure-support revenue from its installed base of 50+ units globally across the United States, China, Australia, Europe, and Asia Pacific. As of Q1 2024, over 25,000 procedures had been completed on the platform, generating a corpus of peer-reviewed clinical evidence that supports go-to-market efforts. Biobot employs 11–50 staff across three regional offices (Singapore, Saint Paul MN, Shanghai) and is led by an operations and technology team under the chairmanship of ZIG Ventures/Zicom Group founder Sim Giok Lak, with MicroPort Medbot CEO He Chao on the board.

Biobot has raised approximately US$39.5M across multiple financing rounds from 2023 through 2026, with ZIG Ventures as the consistent lead investor. The company's go-to-market relies on clinical evidence, KOL engagement, and a clinical advisory network, targeting urologists and hospital procurement systems seeking to address the clinical gap left by traditional transrectal biopsies, which carry 3–5% infection risk and detect only 23% of clinically significant cancers.

Name

Biobot Surgical Pte Ltd

Legal name

BIOBOT SURGICAL PTE LTD

Website

https://biobotsurgical.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Biobot Surgical Pte Ltd is a Singapore-based medical robotics company that develops the iSR'obot Mona Lisa robotic platform for transperineal prostate biopsy and ablation procedures, serving urologists and hospitals globally with 50+ installed units and regulatory clearances across FDA, CE, NMPA, TGA, and HSA markets.

Ownership category

akta.pro rank

Product category

Surgical Robotics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)

akta.pro secondary industries

Healthcare & Assistive Robotics (HDAAAIAC), Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH), Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG), Endourology & Minimally Invasive Urologic Surgery (HLAKAOAF)

Keywords

• Robotic surgical systems
• Prostate biopsy devices
• Medical robotics platforms
• Transperineal biopsy equipment
• Surgical navigation technology

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. Mona Lisa Robotic System Sales: Sale of the iSR'obot Mona Lisa robotic platform for prostate biopsy and ablation procedures. System includes hardware components and integrated software for MRI-ultrasound fusion imaging.
2. Procedure-related Revenue: Revenue generated from consumables and procedure support for the installed base of 50+ units globally, completing over 25,000 procedures.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Biobot Surgical develops and sells the iSR'obot Mona Lisa robotic platform for transperineal prostate procedures, combining MRI-ultrasound fusion imaging with robotic-assisted needle positioning. The portfolio includes Mona Lisa [Dx] for targeted prostate biopsies and Mona Lisa 2.0 [Tx] which adds indications for soft tissue ablation treatment positioning, supported by proprietary Dual Cone Technology and an installed base of 50+ units globally.

Product overview

Biobot Surgical offers a robotic-assisted surgical platform for prostate disease management centered on the iSR'obot Mona Lisa system. The portfolio consists of two product generations: Mona Lisa [Dx] (first generation, launched 2017) for targeted prostate biopsies, and Mona Lisa 2.0 [Tx] (second generation) which extends functionality to include soft tissue ablation treatment. Both versions utilize the same core robotic platform featuring MRI-ultrasound fusion technology, dual cone technology for maximal prostate coverage, and sub-millimeter robotic accuracy for needle positioning. The system enables transperineal (percutaneous) prostate procedures with minimal infection risk compared to traditional transrectal approaches. The company also offers ACCuESS as an innovation pipeline expansion for expanding sites of care.

Differentiator

Problem solved

Functional benefit

Brands

• iSR'obot: Robotic platform brand name for the Mona Lisa system.
• Mona Lisa

Products and services

• iSR'obot Mona Lisa [Dx] A cutting-edge robotic system for transperineal prostate targeted biopsies. Combines MRI-ultrasound fusion guidance with robotic-assisted needle positioning to achieve sub-millimeter accuracy within 1.0mm. Includes automated biopsy planning, dual cone technology for maximal prostate coverage, and compatibility with existing imaging workflows. Holds FDA, NMPA, TGA and HSA clearances.
• Mona Lisa 2.0 [Tx] Second-generation robotic system that expands indications beyond diagnostic biopsy to include positioning for soft tissue ablation treatment. Features robotic accuracy, MRI-ultrasound fusion, and dual cone technology with enhanced workflow capabilities for ablation planning including visual overlays of lesion margins and simulated ablation zones. Holds FDA, CE, TGA and HSA clearances.

Quantifiable outcome

• Robotic-assisted needle positioning accuracy within 1.0mm
• +4 more outcomes

Named customers12 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Intuitive Surgical: Global leader in surgical robotics with the da Vinci platform. While its prostate focus is broader (multi-specialty) and it does not specialize in transperineal biopsy, it is the dominant force in robotic-assisted urological surgery and represents both a benchmark and a competitive threat to Biobot's positioning.
• Philips: Global medtech and imaging player with interventional guidance and image-guided therapy offerings. Comparable as an imaging-led incumbent that could expand into robotic-assisted biopsy or treatment, leveraging its installed MRI/ultrasound base.
• Siemens Healthineers: Major imaging and image-guided therapy provider whose MRI and ultrasound platforms underpin much of the imaging workflow Biobot's fusion technology requires. A potential ecosystem partner or competitor as imaging-native companies expand into robotic guidance.
• Medtronic: Hugo robotic-assisted surgery platform represents Medtronic's challenge to Intuitive in soft-tissue robotics. With massive R&D and global hospital channel access, Medtronic is a credible entrant into urological robotics that could pressure Biobot's market position.
• Johnson & Johnson (MONARCH/Johnson & Johnson MedTech): Through its MONARCH platform (bronchoscopy robotics) and Ottava program, J&J is positioning aggressively in surgical robotics. The combination of capital, hospital relationships and broader surgical ecosystem makes it a long-term competitive threat across urology and adjacent indications.

Direct peers

• MicroPort MedBot: Chinese surgical robotics company whose CEO He Chao sits on Biobot's board. MedBot's Toumai laparoscopic robot competes in overlapping geographies; the strategic overlap creates both partnership upside and competitive risk for Biobot.
• PROCEPT BioRobotics: Direct urology robotics competitor with the AquaBeam system for waterjet-based prostate tissue ablation. Targets the same urology call point and is expanding indications in prostate disease management, making it the most directly comparable commercial-stage peer.
• Accuray: Developer of the CyberKnife and TomoTherapy radiation therapy robotics systems serving urological oncology. Targets similar patient populations (prostate cancer) with a different modality and competes for hospital capital budgets in urology service lines.

Emerging players

• THINK Surgical: Developer of the TSolution One robotic system for orthopedic surgery. Comparable as a niche, category-defining surgical robotics company that pioneered computer-assisted surgery in its specialty before larger incumbents entered.
• Renishaw: UK-based precision engineering company with neurosurgical robotics (Neuromate) and significant expertise in image-guided, precision positioning systems. Comparable in applying high-accuracy robotic positioning to clinical procedures, though in different anatomical specialties.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/biobotmonalisa

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biobot Surgical Pte Ltd